文献速递眼底病与葡萄膜炎

生物类似药FYB201与雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效与安全性比较

Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2021-05-03

这项前瞻性、多中心、评估者设盲、平行组、48周III期随机研究纳入477例未治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,随机接受FYB201(n=238)或参照雷珠单抗(n=239)0.5 mg每4周玻璃体腔注射。第8周时,FYB201组和参照雷珠单抗组最佳矫正视力(BCVA)平均分别提高+5.1和+5.6个ETDRS字母,两组间最小二乘均值差为-0.4个ETDRS字母(90%CI -1.6至0.9),落在预设的3个字母等效界值内;不良事件两组相当。结论认为FYB201在临床疗效及眼部和全身安全性方面与参照雷珠单抗生物类似。

要点

  • FYB201与参照雷珠单抗在nAMD患者第8周BCVA变化上的最小二乘均值差为-0.4个ETDRS字母(90%CI -1.6至0.9),满足等效性。
  • 两组BCVA平均改善分别为+5.1(FYB201)和+5.6(参照雷珠单抗)个ETDRS字母。
  • 不良事件在FYB201与参照雷珠单抗两组间相当。

核心结论

  • FYB201在治疗nAMD患者中,临床疗效以及眼部和全身安全性方面与参照雷珠单抗生物类似。

研究设计与样本

  • 前瞻性、多中心、评估者设盲、平行组、48周III期随机研究。
  • 共477例未治疗的新生血管性年龄相关性黄斑变性(nAMD)患者随机分配至FYB201组(n=238)或参照雷珠单抗组(n=239)。
  • 两组均接受0.5 mg玻璃体腔注射,每4周一次。

主要发现

  • 第8周时,FYB201组BCVA平均改善+5.1个ETDRS字母,参照雷珠单抗组平均改善+5.6个ETDRS字母。
  • 协方差分析(ANCOVA)显示,两组基线至第8周BCVA变化的最小二乘均值差为-0.4个ETDRS字母(90%CI -1.6至0.9)。
  • 90%CI落在预设的3个ETDRS字母等效界值内,主要终点达成。
  • 不良事件在两组治疗间相当。

关键数值与推荐

  • 主要终点为第3次每月玻璃体腔注射前第8周时BCVA较基线的变化(ETDRS字母数)。
  • 生物类似性通过双侧等效检验评估,BCVA等效界值为3个ETDRS字母。
  • FYB201与参照雷珠单抗的BCVA变化最小二乘均值差为-0.4个ETDRS字母(90%CI -1.6至0.9),在等效界值内。

临床怎么用

  • 对于未治疗的nAMD患者,FYB201可作为参照雷珠单抗的生物类似药选择,其疗效和安全性在III期研究中得到验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial was conducted to investigate the clinical equivalence of the proposed biosimilar FYB201 and reference ranibizumab in patients with treatment-naive, subfoveal choroidal neovascularization caused by neovascular age-related macular degeneration (nAMD). DESIGN: This was a prospective, multicenter, evaluation-masked, parallel-group, 48-week, phase III randomized study. PARTICIPANTS: A total of 477 patients were randomly assigned to receive FYB201 (n = 238) or reference ranibizumab (n = 239). METHODS: Patients received FYB201 or reference ranibizumab 0.5 mg by intravitreal (IVT) injection in the study eye every 4 weeks. MAIN OUTCOME MEASURES: The primary end point was change from baseline in best-corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at 8 weeks before the third monthly IVT injection. Biosimilarity of FYB201 to its originator was assessed via a 2-sided equivalence test, with an equivalence margin in BCVA of 3 ETDRS letters. RESULTS: The BCVA improved in both groups, with a mean improvement of +5.1 (FYB201) and +5.6 (reference ranibizumab) ETDRS letters at week 8. The analysis of covariance (ANCOVA) least squares mean difference for the change from baseline between FYB201 and reference ranibizumab was -0.4 ETDRS letters with a 90% confidence interval (CI) of -1.6 to 0.9. Primary end point was met as the 90% CI was within the predefined equivalence margin. Adverse events were comparable between treatment groups. CONCLUSIONS: FYB201 is biosimilar to reference ranibizumab in terms of clinical efficacy and ocular and systemic safety in the treatment of patients with nAMD.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Holz FG, Oleksy P, Ricci F, et al. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021. PMID: 33957183. doi:10.1016/j.ophtha.2021.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。